XNApharma GmbH
Dr. Tobias Pöhlmann
Ronneburger Straße 74
07546 Gera

Phone: +49 365 77347180
https://xnapharma.com

XNApharma -
Oligonucleotides for life.
  • zoom website
  • print preview

Developing oligonucleotide therapies

Technology platform

Target cell specificity is the key for a highly potent and well tolerated cancer therapy. XNApharma is developing oligonucleotides which are selectively active in cancer cells.

Find out more

Preclinical development

XNApharma is the leader in Peptide-siRNA prodrugs. We are focused on protease functionality and optimisation, siRNA design and modification as well as preclinical development.

Find out more

Clinical Strategy

Developing a strategy to fight cancer is our goal. Therefore, we are developing several scientific and clinical strategies as well as a straight GMP manufacturing approach.

Find out more

Source: https://xnapharma.com/

Science dedicated to human health

Science dedicated to human health

XNApharma Gera
Copyright© XNApharma GmbH

Contact information

XNApharma GmbH
Ronneburger Straße 74
07546 Gera | Germany

Phone: +49 365 77347180
 
Manage your consents

Use the website comfortably and informatively - Agree now!

To make your visit to this website as comfortable and informative as possible, we use cookies and online services of third parties. For data protection reasons, these third-party online services (including cookies) may only be used after you have given your consent. Which online services are involved can be found in the details / settings or in the privacy policy. You can also revoke consents already granted here.